BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05176639 (VRDN 001 in Thyroid Eye Disease): BVCT ex-ante prediction vs. reported outcome

On 14 Feb 2024, BioinvestGPT's BVCT predicted technical success and commercial partial success for this trial. The 10 Sep 2024 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient (non-superior to teprotumumab).

Clinical Trial

NCTID
NCT05176639
Acronym
THRIVE
Drug Name
VRDN 001
Drug MoA
anti-IGF1R mAb inhibitor
Drug Modality
monoclonal antibody
Drug Class
Best-In-Class
Therapeutic Area
Eye Diseases
Indication
Thyroid Eye Disease (TED)
Human Patients
154
Sponsor
Viridian Therapeutics
Phase
Phase 3

Prediction of , index 906

Prospective Prediction
Prediction Index
906
Prediction Date
Commercial Prediction
partial SUCCESS (commercially sufficient clinical benefit non-superior to Tepezza)
Technical Prediction
SUCCESS (statistically significant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
209 days in advance
Readout Data Interpretation
VRDN001 achieved 64% placebo-adjusted PRR at week 15 vs. 65% placebo-adjusted PRR at week 15 achieved by the SoC teprotumumab in NCT03298867.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient (non-superior to teprotumumab)
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Safety, Tolerability, and Efficacy Study of Veligrotug, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor in Subjects With Thyroid Eye Disease
Phase
Phase 3
Status
Completed
Enrollment
113
Lead sponsor
Viridian Therapeutics, Inc.
Conditions
Thyroid Eye Disease
Interventions
DRUG: Veligrotug; DRUG: Placebo
Design
Randomized · Parallel · Triple
Primary purpose
Treatment
Start
2022-11-16
Primary completion
2024-07-15
Completion
2025-03-27
Results first posted
2026-08-13
Primary outcomes
  • Proptosis Responder Rate (PRR) in the Study Eye As Measured by Exophthalmometer (Baseline to Week 15)

NCT05176639 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials